FDA Might Seek "Intermediate" Action Authority To Enforce Trial Compliance
This article was originally published in The Gray Sheet
Executive Summary
FDA is considering whether to ask Congress for the authority to bring "intermediate" enforcement actions against parties violating clinical trial regs, FDA Office of Regulatory Affairs Director of Enforcement Daniel Michels told the Government Reform/Criminal Justice, Drug Policy and Human Resources Subcommittee.